Diabetic Nephropathy News Archive
Biomarkers apoA4, CD5L, C1QB, and IBP3 may improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in T2DM.
Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.
Almost 40% of pre-dialysis patients with stage 4-5 CKD patients and type 2 diabetes had lab results suggesting low turnover bone disease.
There was a significant association for Trp with the event of rapid decline in eGFR.
Higher levels of sRAGE were significantly associated with incidence of DN after adjustment for duration of diabetes.
Of the children who developed acute kidney injury, 34.9% had stage 1, 45.3% had stage 2, and 19.8% had stage 3.
DPP-4 inhibitors use was used in 54% of treatment visits by the last quarter of 2014; ACEIs and ARBs were prescribed in the majority of treatment visits with peaks above 90%.
Valsartan reduced the incidence of microalbuminuria in IGT without increasing the incidence of hyperkalemia or renal dysfunction compared with placebo.
Poor glycemic control linked to increased prevalence and severity of periodontitis.
Use of the glucagon-like peptide-1 receptor agonist lowered 24-hour urinary albumin excretion rate by 32% over 12 weeks versus placebo.
Findings in large cohort of patients with diabetes over 4 years of follow-up.
AGEs improve RFL prediction in American-Indians with type 2 diabetes.
No change in overall prevalence from 1988 to 2014; decrease in albuminuria, increase in reduced eGFR.
Incident or worsening nephropathy was observed in 12.7% of patients receiving empagliflozin compared with 18.8% of those receiving placebo.
Length of time spent in remission inversely related to risk of microvascular disease.
Renal function decline is independent factor for cardiovascular risk in patients with type 2 diabetes.
Diabetic nephropathy lesions may develop prior to the onset of clinical findings.
Athcar gel may be a treatment option for patients with treatment-resistant nephrotic syndrome.
Increase in prevalence from 2002-2013, with highest prevalence among those aged 12 to less than 18 years.
The medication significantly decreased potassium levels over 52 weeks in patients with resistant hypertension and diabetic kidney disease.
Higher urinary potassium excretion, not sodium excretion, tied to lower risk of primary end point.
AKI, albuminuria, eGFR considered separately or together can predict adverse outcomes in diabetes.
Significant association found in patients with diabetic nephropathy.
Hyperkalemia occurred in just 1.8% of patients taking finerenone 7.5 to 20 mg daily.
Nonalbuminuric chronic kidney disease was linked to increases in all-cause and cardiovascular mortality, but not albuminuria or end-stage renal disease.
Older patients with more diabetes complications have greater cognitive decline, study finds.
Increased uric acid levels were correlated with decreased HbA1c and increased prevalence of diabetic kidney disease, study finds.
Intense glycemic control was significantly linked to higher risks of cardiovascular and all-cause mortality
Among the increased risks, women with the disease had an 86% higher chance of dying from cardiovascular disease than men.
Researchers in the Netherlands report results from an autopsy study of diabetic nephropathy patients.
Researchers find an independent association in a study of Japanese patients with type 2 diabetes.
Public health efforts needed to ensure adequate access to ophthalmologists.
The drug maintained kidney function in mice with diabetic nephropathy.
A trial of a gluten-free diet presents no inherent risk for patients starting to exhibit microvascular damage.
Among Canadian diabetics, end-stage renal disease is almost three times more likely to development among First Nation adults.
ACE inhibitor plus ARB failed to slow disease progression but increased acute kidney injury risk.
Diabetic nephropathy was the cause of ESRD in 62.8% of patients, study shows.
New treatments that restore and increase mitochondrial function and content could ameliorate or even arrest CKD, according to investigators.
Nearly twofold decrease observed in the proportion of patients with advanced diabetic nephropathy who progress to end-stage renal disease.
Lower creatinine excretion rate linked to higher all-cause mortality in type 2 diabetes, nephropathy
Minorities more likely to have proteinuric DKD; less likely to have nonproteinuric DKD.
Minorities also are less likely than non-Hispanic whites to have nonproteinuric diabetic kidney disease.
ACE inhibitor plus an angiotensin receptor blocker was not more effective than either drug alone in patients with diabetic nephropathy.
Improved renal and cardiovascular protection observed in patients with type 2 diabetic nephropathy.
Silymarin significantly decreased UACR compared with placebo in patients with diabetic nephropathy.
Patients with type 2 diabetic nephropathy are more likely to progress to end-stage renal disease (ESRD) than die, according to investigators.
ACE inhibitor of ARB use decreased progression risk in patients with macroalbuminuria at baseline.
Podocytes demonstrate a strong reliance on insulin to function properly, according to a study published in Cell Metabolism (2010;12:329-340).
Researchers have found a seasonal variation in urinary albumin-to-creatinine ratio (UACR) in Japanese patients with type 2 diabetes and early nephropathy, with the highest values in winter and the lowest in summer.
The albumin:creatinine ratio in the first urine excreted in the morning is better than 24-hour urinary albumin excretion in determining the risk for renal events in patients with type 2 diabetes and nephropathy, data show.
Patients with diabetic nephropathy should avoid taking high doses of B vitamins to lower homocysteine levels.
Renal disease patients who have persistent proteinuria despite treatment with the highest approved dosage of the angiotensin receptor blocker candesartan may benefit from higher dosages, a Canadian study finds.
SAN FRANCISCO—British researchers have endorsed U.S. guidelines stating that screening diabetic patients for renal disease should involve estimated glomerular filtration rate (eGFR) in addition to testing for albuminuria.
Aliskiren, an oral direct renin inhibitor, may have renoprotective effects that are independent of its BP-lowering effect in patients with type 2 diabetic nephropathy who are receiving the maximal recommended renoprotective treatment and optimal antihypertensive therapy, researchers report.
Intensive glucose control with gliclazide (modified release) and other agents reduced the risk of nephropathy by one fifth in a large study of patients with type 2 diabetes.
End-stage renal disease (ESRD) is affecting a growing proportion of type 2 diabetics in Australia and New Zealand, a study found.
CHICAGO—Telmisartan (Micardis HCT), a novel angiotensin receptor blocker (ARB), and the older ARB losartan have similar BP-lowering efficacy in hypertensive patients with diabetic nephropathy, but treatment with the new agent is associated with larger reductions in proteinuria, new findings show.
Renal hypertrophy is a major factor in the development of diabetic nephropathy in patients with type 1 diabetes.
Eli Lilly and Company has received an approvable letter from the FDA requesting additional supporting data for its new drug application for ruboxistaurin mesylate (proposed trade name: Arxxant), Lilly's investigational oral therapy for diabetic retinopathy.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)